WBIO — WPD Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- CA$0.32m
- CA$0.71m
Annual income statement for WPD Pharmaceuticals, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 January 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.796 | 8.39 | 6.82 | -1.98 | 0.263 |
| Operating Profit | -0.796 | -8.39 | -6.82 | 1.98 | -0.263 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.779 | -7.52 | -5.62 | 3.86 | -0.08 |
| Net Income After Taxes | -0.779 | -7.52 | -5.62 | 3.86 | -0.08 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.779 | -7.52 | -5.62 | 3.86 | -0.08 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.779 | -7.52 | -5.62 | 3.86 | -0.08 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.795 | -1.66 | -1.19 | -0.14 | -0.019 |